SCHEMBL20119640

SCHEMBL20119640

Clc1nc(NCc2ccncn2)c2cc[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 1/20 0.40
TTBK1 Q5TCY1 4/20 0.36
TTBK2 Q6IQ55 4/20 0.36
PDE5A O76074 1/20 0.35
APP P05067 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
JAK2 O60674 3/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 2/20 0.35
AURKB Q96GD4 2/20 0.35
IGF1R P08069 1/20 0.35
PIM1 P11309 1/20 0.35
SRC P12931 1/20 0.35
CSNK2A2 P19784 1/20 0.35
KCNA5 P22460 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119610 0.83 JAK2 (0.51) PDE5AAPPKDM4EALDH1A1HPGD
SCHEMBL20119612 0.82 EGFR (0.38) TTBK1TTBK2PDE5AAPPKDM4E
SCHEMBL29833956 0.81 PDE5A (0.48) KCNH3TTBK1TTBK2PDE5AAPP
SCHEMBL20119397 0.81 PDE5A (0.48) KCNH3TTBK1TTBK2PDE5AAPP
SCHEMBL17933806 0.81 PLK4 (0.41) KCNH3PDE5AAPPALDH1A1JAK2
SCHEMBL20119693 0.80 KCNH3 (0.40) KCNH3JAK2JAK1TYK2JAK3
SCHEMBL20119739 0.79 KCNH3 (0.38) KCNH3PDE5AAPPKDM4EALDH1A1
SCHEMBL20119845 0.79 APP (0.44) KCNH3TTBK1TTBK2PDE5AAPP
SCHEMBL20119909 0.79 CDK2 (0.39) KCNH3JAK2JAK1TYK2JAK3
SCHEMBL20119892 0.78 KCNH3 (0.43) KCNH3JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885TTBK1 2269/4885TTBK2 2553/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885TTBK1 2269/4885TTBK2 2553/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885TTBK1 2269/4885TTBK2 2553/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885TTBK1 2269/4885TTBK2 2553/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885TTBK1 2269/4885TTBK2 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.